Immune Checkpoint Inhibitors Have Transformed Cancer Treatment – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Anniek Strijdhorst et al, adding:
“Immune checkpoint inhibitors and thrombosis: are antiphospholipid antibodies to blame?
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, but they are associated with an increased risk of both venous and arterial thromboembolism. The mechanisms behind this remain poorly understood.
One hypothesis: ICI therapy might trigger the development of antiphospholipid antibodies, leading to hypercoagulability.
A new prospective study from the ITHACA cohort, published in RPTH Journal, puts this hypothesis to the test.
- Key findings from 40 patients assessed before and after 3 months of ICI therapy:
- No significant development of antiphospholipid antibody positivity after 3 months (8% at baseline vs 5% at 3 months)
- No patients developed a positive lupus anticoagulant
- Thrombin generation remained unchanged
- Only 1 patient developed VTE during follow-up
The short-term thrombotic risk associated with ICI therapy does not appear to be mediated by antiphospholipid antibodies, pointing researchers toward other mechanisms that still need to be uncovered.”
Title: Antiphospholipid antibody formation during immune checkpoint inhibition in patients with cancer: a prospective cohort study
Authors: Anniek Strijdhorst, Dorien M. Salet, Jente M. Schoenaker, Vossa van der Vegte, Tom T.P. Seijkens, Hanneke W.M. van Laarhoven, Rolf T. Urbanus, Nick van Es

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines